Chicago’s biotech scene just landed a blockbuster exit. Teva Pharmaceutical Industries has closed its acquisition of Emalex Biosciences, the hometown company built by Paragon to advance the experimental Tourette syndrome drug ecopipam, in a deal worth up to $900 million. Teva paid $700 million at closing on Wednesday, with Emalex shareholders in line for up to $200 million more in milestone payments and net sales royalties. The buyout drops a late-stage, first-in-class Tourette candidate into Teva’s neuroscience portfolio and puts a concrete regulatory clock on the wall.
In a press release on Wednesday, Teva said it paid $700 million at closing and that Emalex shareholders may receive up to $200 million in commercial milestone payments, plus royalties, if regulators sign off. The company cast the buy as part of its "Pivot to Growth" strategy and said ecopipam will be folded into its global neuroscience push.
Clinical Data And Next Steps
Positive Phase 3 results for ecopipam were published May 26 in JAMA Neurology. The data showed the drug significantly reduced risk of relapse in pediatric patients (p = 0.0084) and was generally well tolerated. Emalex and Teva have said a U.S. New Drug Application is anticipated in the second half of 2026, a key regulatory milestone that would officially start the path to patient access.
Paragon And Chicago's Role
Emalex was created and backed by Paragon Biosciences, which lists a downtown Chicago address and says it pushed the program to late stage readiness. Jeff Aronin, Paragon's CEO and Emalex chairman, said in Teva's statement, "We built Emalex around a clear patient need and advanced ecopipam to late-stage readiness with speed and precision." The sale is another example of Paragon incubating specialized biotech assets, then handing them off to a global pharma player once they are primed for prime time.
Why The Deal Matters
For Teva, the acquisition delivers a registration ready neuroscience asset that could widen its innovative medicine lineup and help rebalance the company’s revenue mix. Industry outlets have pointed out that the deal fits neatly alongside Teva’s late stage pipeline and puts a potentially differentiated Tourette therapy on a quicker road to market, as reported by American Pharmaceutical Review.
Chicago's life sciences community, meanwhile, will be watching the NDA timeline and the ripple effects for local R&D jobs and investors, as Crain's Chicago Business reported. If regulators clear ecopipam, patients and families navigating Tourette syndrome could see a new treatment option arrive within years rather than decades.
